Symbols / MRKR
MRKR Chart
About
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 21.09M |
| Enterprise Value | 9.59M | Income | -14.30M | Sales | 4.69M |
| Book/sh | 1.10 | Cash/sh | 1.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -2.06 | PEG | — |
| P/S | 4.49 | P/B | 1.48 | P/C | — |
| EV/EBITDA | — | EV/Sales | 2.04 | Quick Ratio | 5.75 |
| Current Ratio | 6.50 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.17 | EPS next Y | -0.79 | EPS Growth | — |
| Revenue Growth | -36.00% | Earnings | 2025-11-13 17:00 | ROA | -55.20% |
| ROE | -110.67% | ROIC | — | Gross Margin | -193.12% |
| Oper. Margin | -173.30% | Profit Margin | 0.00% | Shs Outstand | 12.94M |
| Shs Float | 13.81M | Short Float | 3.72% | Short Ratio | 0.46 |
| Short Interest | — | 52W High | 4.07 | 52W Low | 0.81 |
| Beta | 1.41 | Avg Volume | 377.00K | Volume | 263.87K |
| Target Price | $7.87 | Recom | None | Prev Close | $1.47 |
| Price | $1.63 | Change | 10.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.87
Mean price target
2. Current target
$1.63
Latest analyst target
3. DCF / Fair value
$-15.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.63
Low
$5.60
High
$10.00
Mean
$7.87
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-04-01 | reit | WBB Securities | Strong Buy → Strong Buy | $13 |
| 2025-03-05 | init | Canaccord Genuity | — → Buy | $8 |
| 2024-04-30 | init | Ladenburg Thalmann | — → Buy | $11 |
- MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Yahoo Finance Wed, 21 Jan 2026 08
- HC Wainwright & Co. Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq Mon, 08 Dec 2025 08
- Would You Still Hold Marker Therapeutics Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
- MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Zacks Investment Research Wed, 21 Jan 2026 08
- Good Morning America puts Baylor T-cell cancer trial in national spotlight - Stock Titan Mon, 26 Jan 2026 08
- H.C. Wainwright reiterates Buy rating on Marker Therapeutics stock - Investing.com Mon, 08 Dec 2025 08
- Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - simplywall.st Mon, 12 Jan 2026 08
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire Fri, 14 Nov 2025 08
- Marker Therapeutics Sets Date for 2026 Annual Meeting - TipRanks Mon, 09 Feb 2026 08
- Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely - Yahoo Finance hu, 18 Dec 2025 08
- 66% Response Rate: Marker's Novel T Cell Therapy Shows Promise for CAR-T Resistant Lymphoma Patients - Stock Titan ue, 26 Aug 2025 07
- Marker Therapeutics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st Sat, 16 Aug 2025 07
- Brookline Capital raises Marker Therapeutics stock price target to $5.60 - Investing.com Mon, 05 Jan 2026 08
- Marker Therapeutics Reports Positive Phase 1/2 Clinical Study Results for Multi-Antigen Targeted T Cells in Pancreatic Cancer Patients - Quiver Quantitative Mon, 05 Jan 2026 08
- MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11085 | 35472 | — | Purchase at price 3.20 per share. | ELMS STEVEN A | Director | — | 2024-12-23 00:00:00 | I |
| 1 | 554250 | 1773600 | — | Purchase at price 3.20 per share. | NEW ENTERPRISE ASSOCIATES 16, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-23 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.53M | -11.27M | -19.79M | -36.32M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.73M | -14.05M | -19.78M | -41.88M |
| ReconciledDepreciation | 3.68M | 3.16M | ||
| EBITDA | -4.53M | -11.27M | -19.79M | -36.32M |
| EBIT | -4.53M | -11.27M | -19.79M | -39.48M |
| NetInterestIncome | 437.01K | 539.16K | 248.06K | 5.70K |
| InterestIncome | 437.01K | 539.16K | 248.06K | 5.70K |
| NormalizedIncome | -10.73M | -14.05M | -19.78M | -41.88M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.73M | -8.24M | -29.93M | -41.88M |
| TotalExpenses | 11.12M | 14.58M | 19.79M | 39.48M |
| TotalOperatingIncomeAsReported | -11.12M | -14.58M | -19.79M | -39.48M |
| DilutedAverageShares | 8.98M | 8.81M | 8.35M | 7.65M |
| BasicAverageShares | 8.98M | 8.81M | 8.35M | 7.65M |
| DilutedEPS | -1.19 | -0.94 | -3.58 | -5.47 |
| BasicEPS | -1.19 | -0.94 | -3.58 | -5.47 |
| DilutedNIAvailtoComStockholders | -10.73M | -8.24M | -29.93M | -41.88M |
| NetIncomeCommonStockholders | -10.73M | -8.24M | -29.93M | -41.88M |
| NetIncome | -10.73M | -8.24M | -29.93M | -41.88M |
| NetIncomeIncludingNoncontrollingInterests | -10.73M | -8.24M | -29.93M | -41.88M |
| NetIncomeDiscontinuousOperations | 0.00 | 5.81M | -10.15M | |
| NetIncomeContinuousOperations | -10.73M | -14.05M | -19.78M | -41.88M |
| TaxProvision | 49.95K | 3.67K | 0.00 | |
| PretaxIncome | -4.09M | -10.73M | -19.78M | -41.88M |
| OtherIncomeExpense | -232.97K | -2.41M | ||
| OtherNonOperatingIncomeExpenses | -232.97K | -2.41M | ||
| NetNonOperatingInterestIncomeExpense | 437.01K | 539.16K | 248.06K | 5.70K |
| InterestIncomeNonOperating | 437.01K | 539.16K | 248.06K | 5.70K |
| OperatingIncome | -4.53M | -11.27M | -19.79M | -39.48M |
| OperatingExpense | 11.12M | 14.58M | 19.79M | 39.48M |
| OtherOperatingExpenses | -6.59M | -3.31M | -3.51M | -1.24M |
| ResearchAndDevelopment | 13.47M | 10.42M | 11.97M | 27.79M |
| SellingGeneralAndAdministration | 4.24M | 7.48M | 11.34M | 12.92M |
| GeneralAndAdministrativeExpense | 4.24M | 7.48M | 11.34M | 12.92M |
| OtherGandA | 4.24M | 7.48M | 11.34M | 12.92M |
| TotalRevenue | 6.59M | 3.31M | 0.00 | 0.00 |
| OperatingRevenue | 6.59M | 3.31M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.71M | 8.90M | 8.40M | 8.31M |
| ShareIssued | 10.71M | 8.90M | 8.40M | 8.31M |
| TotalDebt | 7.62M | 11.87M | ||
| TangibleBookValue | 18.56M | 14.05M | 19.60M | 43.99M |
| InvestedCapital | 18.56M | 14.05M | 19.60M | 43.99M |
| WorkingCapital | 18.56M | 14.05M | 8.84M | 33.08M |
| NetTangibleAssets | 18.56M | 14.05M | 19.60M | 43.99M |
| CapitalLeaseObligations | 7.62M | 11.87M | ||
| CommonStockEquity | 18.56M | 14.05M | 19.60M | 43.99M |
| TotalCapitalization | 18.56M | 14.05M | 19.60M | 43.99M |
| TotalEquityGrossMinorityInterest | 18.56M | 14.05M | 19.60M | 43.99M |
| StockholdersEquity | 18.56M | 14.05M | 19.60M | 43.99M |
| RetainedEarnings | -447.02M | -436.29M | -428.05M | -398.12M |
| AdditionalPaidInCapital | 465.56M | 450.33M | 447.64M | 442.10M |
| CapitalStock | 10.71K | 8.89K | 8.41K | 8.31K |
| CommonStock | 10.71K | 8.89K | 8.41K | 8.31K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.46M | 3.07M | 14.82M | 24.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 7.04M | 11.25M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 7.04M | ||
| LongTermDebtAndCapitalLeaseObligation | 7.04M | 11.25M | ||
| LongTermCapitalLeaseObligation | 7.04M | 11.25M | ||
| CurrentLiabilities | 3.46M | 3.07M | 7.78M | 12.90M |
| OtherCurrentLiabilities | 954.00 | 193.00 | 5.26M | -87.00 |
| CurrentDeferredLiabilities | 2.50M | 1.15M | ||
| CurrentDeferredRevenue | 2.50M | 1.15M | ||
| CurrentDebtAndCapitalLeaseObligation | 577.20K | 620.49K | ||
| CurrentCapitalLeaseObligation | 577.20K | 620.49K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 86.00K | 57.00K | 750.00K | 2.06M |
| PayablesAndAccruedExpenses | 3.38M | 3.02M | 1.77M | 9.08M |
| CurrentAccruedExpenses | 497.00K | 508.00K | 670.00K | 3.94M |
| Payables | 2.88M | 2.51M | 1.10M | 5.14M |
| DuetoRelatedPartiesCurrent | 1.71M | 1.33M | 0.00 | |
| TotalTaxPayable | 104.00K | 219.00K | 0.00 | |
| AccountsPayable | 1.07M | 961.00K | 1.10M | 5.14M |
| TotalAssets | 22.02M | 17.13M | 34.42M | 68.14M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 17.80M | 22.15M |
| OtherNonCurrentAssets | 17.80M | |||
| NetPPE | 17.80M | 22.15M | ||
| AccumulatedDepreciation | -5.27M | -2.74M | ||
| GrossPPE | 23.08M | 24.89M | ||
| Leases | 3.95M | 3.17M | ||
| ConstructionInProgress | 0.00 | 2.23M | ||
| OtherProperties | 17.30M | 17.68M | ||
| MachineryFurnitureEquipment | 1.82M | 1.81M | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 22.02M | 17.13M | 16.62M | 45.98M |
| AssetsHeldForSaleCurrent | 0.00 | 585.84K | ||
| RestrictedCash | 0.00 | 1.15M | ||
| PrepaidAssets | 483.72K | 988.13K | 1.85M | 2.48M |
| Receivables | 2.35M | 1.03M | 2.40M | 237.00 |
| OtherReceivables | 2.35M | 1.03M | 2.40M | 237.00 |
| CashCashEquivalentsAndShortTermInvestments | 19.19M | 15.11M | 11.78M | 42.35M |
| CashAndCashEquivalents | 19.19M | 15.11M | 11.78M | 42.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.91M | -16.44M | -26.97M | -30.41M |
| IssuanceOfCapitalStock | 14.93M | 1.01M | 202.13K | 52.55M |
| CapitalExpenditure | -4.95M | -3.13M | ||
| EndCashPosition | 19.19M | 15.11M | 11.78M | 43.50M |
| BeginningCashPosition | 15.11M | 11.78M | 43.50M | 21.35M |
| ChangesInCash | 4.08M | 3.33M | -31.72M | 22.14M |
| FinancingCashFlow | 14.99M | 1.11M | 202.13K | 52.56M |
| CashFlowFromContinuingFinancingActivities | 14.99M | 1.11M | 202.13K | 52.56M |
| ProceedsFromStockOptionExercised | 62.16K | 90.48K | 0.00 | 3.09K |
| NetCommonStockIssuance | 14.93M | 1.01M | 202.13K | 52.55M |
| CommonStockIssuance | 14.93M | 1.01M | 202.13K | 52.55M |
| InvestingCashFlow | 0.00 | 18.66M | -4.95M | -3.13M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 18.66M | -4.95M | |
| CashFlowFromContinuingInvestingActivities | -4.95M | -3.13M | ||
| NetPPEPurchaseAndSale | -4.95M | -3.13M | ||
| PurchaseOfPPE | -4.95M | -3.13M | ||
| OperatingCashFlow | -10.91M | -16.44M | -26.97M | -27.28M |
| CashFromDiscontinuedOperatingActivities | 0.00 | -6.10M | -5.46M | |
| CashFlowFromContinuingOperatingActivities | -10.91M | -10.34M | -21.51M | -27.28M |
| ChangeInWorkingCapital | -424.87K | 2.85M | -4.76M | 5.47M |
| ChangeInOtherWorkingCapital | -1.15M | 1.15M | ||
| ChangeInOtherCurrentLiabilities | -513.89K | -388.79K | ||
| ChangeInPayablesAndAccruedExpense | 389.61K | 611.26K | -1.32M | 4.14M |
| ChangeInPayable | 389.61K | 611.26K | ||
| ChangeInAccountPayable | 8.76K | -718.39K | ||
| ChangeInPrepaidAssets | 504.41K | 861.11K | 104.15K | -426.71K |
| ChangeInReceivables | -1.32M | 1.37M | -2.40M | 1.00M |
| OtherNonCashItems | -278.68K | |||
| StockBasedCompensation | 245.86K | 858.27K | 3.30M | 5.96M |
| DepreciationAmortizationDepletion | 3.68M | 3.16M | ||
| DepreciationAndAmortization | 3.68M | 3.16M | ||
| Depreciation | 3.68M | 3.16M | ||
| OperatingGainsLosses | 26.00K | |||
| GainLossOnSaleOfPPE | 26.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -10.73M | -14.05M | -19.78M | -41.88M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MRKR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|